Published in JAMA · View the paper (DOI)
The use of active surveillance for low-risk prostate cancer nearly tripled between 2010 and 2015, with 42.1% of men adopting this strategy. This increase is associated with a favorable prognosis and reduced toxicity from treatment.
Coverage from 2 institutions